• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0
  • HEK293 expressed
  • Endotoxin-free
  • Animal-component free

HumanKine® recombinant human LIF protein- GMP grade

EC50

0.045-0.25 ng/mL

Specific Activity

minimally 3.50 x 106 IU/mg, typically 9.50 x 106 IU/mg

Species Reactivity

human

Purity

>95%

ISO 13485 certified HumanKine® human cell-expressed cytokines and growth factors

Cat No : HZ-1292-GMP

Print datasheet

Synonyms

CDF, D factor, DIA, Emfilermin, HILDA, Leukemia inhibitory factor, LIF, Melanoma derived LPL inhibitor, MLPLI

Validation Data Gallery

  • Purity of recombinant human LIF was determined by SDS- polyacrylamide gel electrophoresis. The protein was resolved in an SDS- polyacrylamide gel in reducing and non-reducing conditions and stained using Coomassie blue.

    Purity of recombinant human LIF was determined by SDS- polyacrylamide gel electrophoresis. The protein was resolved in an SDS- polyacrylamide gel in reducing and non-reducing conditions and stained using Coomassie blue.

  • Recombinant human LIF (HZ-1292-GMP) dose-dependently inhibits growth of the M1 cell line. Cell number was quantitatively assessed by PrestoBlue® Cell Viability Reagent. M1 cells were treated with increasing concentrations of recombinant LIF for 96 hours. The EC50 was determined using a 4-parameter non-linear regression model. Activity determination was conducted in triplicate on a validated bioassay. The EC50 range is 0.045-0.25 ng/mL​.

    Recombinant human LIF (HZ-1292-GMP) dose-dependently inhibits growth of the M1 cell line. Cell number was quantitatively assessed by PrestoBlue® Cell Viability Reagent. M1 cells were treated with increasing concentrations of recombinant LIF for 96 hours. The EC50 was determined using a 4-parameter non-linear regression model. Activity determination was conducted in triplicate on a validated bioassay. The EC50 range is 0.045-0.25 ng/mL​.

Technical Specifications

GeneID 3976
Species Human
Expression HEK293
EC50 0.045-0.25 ng/mL
Specific Activityminimally 3.50 x 106 IU/mg, typically 9.50 x 106 IU/mg
Purity >95%
Endotoxin<0.1 EU/μg
Accession NumberP15018
Molecular Mass 35-55 kDa reduced and non-reduced, glycosylated
Formulation 1x PBS, See Certificate of Analysis for details
Species Reactivity human

Stability and Reconstitution

Stability and StorageProduct FormTemperature ConditionsStorage Time
(From Date of Receipt)
Lyophilized-20°C to -80°CUntil Expiry Date
LyophilizedRoom Temperature2 weeks
Reconstituted as per CofA-20°C to -80°C6 months
Reconstituted as per CofA4°C1 week
Avoid repeated freeze-thaw cycles.
Reconstitution Briefly centrifuge the vial before opening. It is recommended to reconstitute the protein to 0.2 mg/mL in sterile 1x PBS pH 7.4 containing 0.1% endotoxin-free recombinant human serum albumin (HSA). Gently swirl or tap vial to mix.

GMP Quality Policies

HumanKine® GMP (Good Manufacturing Practice) recombinant proteins are manufactured and validated in accordance with ISO 13485 quality management system and is compliant with GMP.
Our GMP recombinant proteins are animal component free (ACF), xeno free (XF) and tag free (TF). Read more about these policies here.

Background

LIF is a pleiotropic cytokine with a variety of roles. It is involved in the induction of hematopoietic differentiation in normal and myeloid leukemia cells, induction of neuronal cell differentiation, regulator of mesenchymal to epithelial conversion during kidney development, and may also have a role in immune tolerance at the maternal-fetal interface (PMID: 29620145; 29391217; 29271384)

Synonyms

CDF, D factor, DIA, Emfilermin, HILDA, Leukemia inhibitory factor, LIF, Melanoma derived LPL inhibitor, MLPLI